ViroPharma Incorporated $225,000,000 2.00% Convertible Senior Notes Due 2017Underwriting Agreement • March 26th, 2007 • Viropharma Inc • Pharmaceutical preparations • New York
ViroPharma Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $225,000,000 principal amount of the 2.00% Convertible Senior Notes due 2017, convertible into shares of Common Stock, par value $0.002 per share (the “Stock”) of the Company specified above (the “Firm Securities”) and, at the election of the Underwriters, up to an aggregate of $25,000,000 additional aggregate principal amount of such Convertible Senior Notes (the “Optional Securities”) (the Firm Securities and the Optional Securities which the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Securities”).
AMENDMENT TO CONFIRMATIONAmendment • March 26th, 2007 • Viropharma Inc • Pharmaceutical preparations • New York
THIS AMENDMENT (this “Amendment”) is made as of this 22nd day of March 2007, between Credit Suisse International (“Dealer”) and ViroPharma Incorporated (“Issuer”).
AMENDMENT TO CONFIRMATIONConfirmation • March 26th, 2007 • Viropharma Inc • Pharmaceutical preparations • New York
THIS AMENDMENT (this “Amendment”) is made as of this 22nd day of March 2007, between Wells Fargo, National Association (“Dealer”) and ViroPharma Incorporated (“Issuer”).
